Small Molecules Regulating the Redox Landscape for Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (15 January 2023) | Viewed by 1969
Special Issue Editor
Special Issue Information
Dear Colleagues,
Reactive oxygen species (ROS) play a crucial role in the regulation of physiological processes; however, deregulated ROS contribute to the development of a large number of human diseases. Consequently, the cellular redox landscape is tightly controlled by complex mechanisms that have been only partially elucidated. As of today, numerous disorders have been linked to the deregulation of ROS homeostasis, including cancer, neurodegenerative diseases and psychiatric disorders. Hence, the redox landscape is an interesting therapeutic target for the development of novel pharmaceuticals. For instance, several therapies attempt to modulate ROS production by inhibiting key players in the redox landscape in order to prevent the development of neuroinflammation in neurodegeneration or the spread of necrosis in ischemic stroke. Other strategies aim to increase ROS production to sensitize cancer cells in radiotherapy or to combat infectious agents. Often, these strategies rely on small molecules that can be classified as various oxidants or antioxidants. More sophisticated approaches employ small molecules that are tailored to selectively inhibit key components of the redox landscape. Our increasing understanding of redox biology in conjunction with advances in chemical biology and medicinal chemistry enable researchers to create novel tools and compounds to modulate the redox landscape in human diseases. This Special Issue aims to summarize the most recent developments in potential therapeutic strategies that make use of small molecules for targeting ROS imbalance and restoring the redox landscape in human diseases.
Dr. Dennis Özcelik
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- small molecules
- drug development
- hypoxia
- oxidative stress response
- reactive oxygen species
- redox homeostasis
- antioxidants
- pharmaceuticals applications
